Drugs / MSCTC-0010
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04385056 | Dec 2020 → Jul 2022 | parkinsonian disorder | IMAC Holdings, Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT03158896 | Jul 2018 → Dec 2025 | acute graft versus host disease | University of Kansas Medical Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSCTC-0010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03158896 ↗ |
| Known as | US-MSCs | “The active ingredient is the umbilical cord-derived allogeneic mesenchymal stem cells (US-MSCs).” NCT04385056 ↗ |
| Modality | Cell therapy | “Wharton's jelly mesenchymal stem cells (MSCTC-0010)” NCT03158896 ↗ |
| Route | Other | “a suspension product for infusion” NCT04385056 ↗ |